URGN Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 108256 min ago

@ $19.19

Ausgestellt: 13 Feb 2024 @ 17:02

Rendite: -26.27%

Vorheriges Signal: Feb 12 - 21:11

Vorheriges Signal: Kaufen

Rendite: -0.20 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases...

Stats
Tagesvolumen	135 619
Durchschnittsvolumen	364 868
Marktkapitalisierung	482.83M
EPS	$0 ( 2024-03-21 )
Nächstes Ertragsdatum	( $-0.930 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.99
ATR14	$0.0290 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Schoenberg Mark	Sell	12 000	Ordinary Shares
2024-01-31	Kim Dong	Buy	3 333	Ordinary Shares
2022-03-25	Kim Dong	Buy	20 000	Stock Option (right to buy)
2024-02-01	Smith Jason Drew	Sell	3 328	Ordinary Shares
2024-02-01	Smith Jason Drew	Sell	1 248	Ordinary Shares

INSIDER POWER
58.83
Last 96 transactions
Buy: 1 308 776 \| Sell: 407 960

Volumen Korrelation

Lang: 0.26 (neutral)

Kurz: -0.02 (neutral)

Signal:(62.511) Neutral

Urogen Pharma Ltd Korrelation

10 Am meisten positiv korreliert
SVAC	0.916
GOODM	0.907
TLGT	0.891
MTSL	0.871
NSTS	0.866
TTWO	0.86
LUNG	0.851
PAIC	0.851
RMNI	0.845
RCM	0.833

10 Am meisten negativ korreliert
LWAC	-0.955
SRAC	-0.919
AMRB	-0.902
LMRKN	-0.889
NETE	-0.881
KNSA	-0.847
UTHR	-0.847
RAVN	-0.84
OFS	-0.831
TECH	-0.828

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Urogen Pharma Ltd Korrelation - Währung/Rohstoff

0.18
( neutral )

0.13
( neutral )

0.00
( neutral )

-0.39
( neutral )

-0.17
( neutral )

0.09
( neutral )

Urogen Pharma Ltd Finanzdaten

Annual	2023
Umsatz:	$82.71M
Bruttogewinn:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2023
Umsatz:	$82.71M
Bruttogewinn:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2022
Umsatz:	$64.36M
Bruttogewinn:	$56.70M (88.11 %)
EPS:	$-4.79

FY	2021
Umsatz:	$48.04M
Bruttogewinn:	$42.89M (89.27 %)
EPS:	$-4.96

Financial Reports:

No articles found.

Urogen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.